Physician profile
Peter C Morris
NPI 1912962994
$2,101.79
in general payments reported to CMS, 2019-2025
29 companies · $260 in 2025
The $260 reported for 2025 was less than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $609 · 2021: $193 · 2022: $290 · 2023: $199 · 2024: $175 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $633.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $381.64 | 2019-2025 | |
| Intuitive Surgical, INC. | $375.66 | 2020-2022 | |
| Glaxosmithkline, LLC. | $267.29 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $248.64 | 2019-2020 | |
| Eisai INC. | $158.84 | 2022-2024 | |
| Pfizer INC. | $112.39 | 2023-2024 | |
| Baxter Healthcare | $90.62 | 2019 | |
| Merck Sharp & Dohme LLC | $62.86 | 2020-2022 | |
| Clovis Oncology, INC. | $36.70 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.68 | 2022-2023 | Ninlaro |
| Seagen INC. | $30.82 | 2022-2023 | Tivdak |
| Mallinckrodt Enterprises LLC | $26.20 | 2019 | |
| Genmab U.S., INC. | $23.52 | 2023 | Epkinly |
| Immunogen, INC. | $21.70 | 2023 | Elahere |
| Mallinckrodt Hospital Products INC. | $20.57 | 2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $20.49 | 2023 | Enhertu |
| Octapharma USA, INC. | $18.51 | 2022 | |
| Amgen INC. | $17.76 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.12 | 2019 | |
| Boston Scientific Corporation | $15.24 | 2025 | Spaceoar Vue System - 10ml |
| Genzyme Corporation | $14.46 | 2022 | |
| G1 Therapeutics, INC. | $14.40 | 2023 | Cosela |
| Genentech USA, INC. | $14.35 | 2019 | |
| Csl Behring | $13.62 | 2022 | |
| Novocure INC. | $13.49 | 2022 | |
| Lilly USA, LLC | $13.30 | 2022 | |
| Sobi, INC | $13.29 | 2022 | |
| Apellis Pharmaceuticals, INC. | $13.15 | 2022 | |
| Taiho Oncology, INC. | $12.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.